One of the most important trends in the pharmaceutical industry is the rapid growth of specialty drugs. Specialty drugs, mostly bio based, tend to be high risk, high priced, and more regulated than traditional drugs, resulting in unprecedented challenges in distribution. Such challenges lead to the emergence of specialty distributors (SDs), which, compared with traditional wholesalers (WSs), represent a more controlled channel and carry a smaller variety of drugs. Due to the risky nature of specialty drugs, manufacturers must consider the trade‐off between access and control in determining whether to use SDs (partially or exclusively). Using a unique dataset assembled from multiple proprietary and public data sources on the transactions for 419 specialty drugs across 11 manufacturers (including 8 of the top 15 manufacturers), 161 distributors, and 129,911 points of care (POCs) in 2012–2015, we investigate how the competing factors of access and control influence manufacturers’ usage of SDs (vs. WSs), with access indicated by downstream POCs’ required product variety and control indicated by regulations on the network. We find that interestingly, the imposition of the regulations in general on the product is not associated with higher usage of SDs, but the imposition of the regulations with a specific element (restrictive access) is. In addition, downstream POCs’ need for convenient access to the required drug variety is associated with lower SD usage. Our study contributes to the limited supply chain literature on risky products and the limited empirical research on Business‐to‐Business (B2B) distribution decisions, and provides important insights and guidance to manufacturers, downstream POCs, and regulators.
AHIP (America's Health Insurance Plans). (2015). Specialty drugs: issues and challenges. https://www.ahip.org/resources/specialty‐drugs‐issues‐and‐challenges
2.
BastaN. (2010). Revenue leakage in biopharma distribution channels is $11 billion annually. https://www.pharmaceuticalcommerce.com/view/revenue‐leakage‐in‐biopharma‐distribution‐channels‐is‐11‐billion‐annually‐says‐idc‐health‐insights
3.
BowersoxD. J. (1969). Physical distribution development, current status, and potential. Journal of Marketing, 33(1), 63–70. https://doi.org/10.1177/002224296903300111
4.
BrillA. (2017). REMS and restricted distribution programs: An estimate of the market. https://accessiblemeds.org/sites/default/files/2018‐04/Alex_Brill_REMS_Study_June_2017.pdf
5.
BrynjolfssonE.HuY.RahmanM. S. (2009). Battle of the retail channels: How product selection and geography drive cross‐channel competition. Management Science, 55(11), 1755–1765. https://doi.org/10.1287/mnsc.1090.1062
6.
BrynjolfssonE.SmithM. D. (2000). Frictionless commerce? A comparison of Internet and conventional retailers. Management Science, 46(4), 563–585. https://doi.org/10.1287/mnsc.46.4.563.12061
7.
BurgosR. M.BadowskiM. E.DrwiegaE.GhassemiS.GriffithN.HeraldF.JohnsonM.SmithR. O.MichienziS. M. (2021). The race to a COVID‐19 vaccine: Opportunities and challenges in development and distribution. Drugs in Context, 10. https://doi.org/10.7573/dic.2020‐12‐2
8.
CachonG. P.KökA. G. (2007). Category management and coordination in retail assortment planning in the presence of basket shopping consumers. Management Science, 53(6), 934–951. https://doi.org/10.1287/mnsc.1060.0661
9.
CachonG. P.OlivaresM. (2010). Drivers of finished‐goods inventory in the US automobile industry. Management Science, 56(1), 202–16. https://doi.org/10.1287/mnsc.1090.1095
10.
ClarkT. S.LinzerD. A. (2015). Should I use fixed or random effects?Political Science Research and Methods, 3(2), 399–408.
11.
ContiR. M.BerndtE. R. (2016). Specialty drug prices and utilization after loss of US patent exclusivity, 2001–2007. In AizcorbeA.BakerC.BerndtE. R.CutlerD. M. (Eds.), Measuring and modeling health care costs (pp. 273–321). University of Chicago Press.
12.
CVS. (2018). Drug trend report 2018. https://payorsolutions.cvshealth.com/insights/2018‐drug‐trend‐report
13.
DukesA. J.GeylaniT.SrinivasanK. (2009). Strategic assortment reduction by a dominant retailer. Marketing Science, 28(2), 309–319. https://doi.org/10.1287/mksc.1080.0399
FeinA. J. (2011). The 2010–11 economic report on pharmaceutical wholesalers. Pembroke Consulting Inc.
16.
FormanC.GhoseA.GoldfarbA. (2009). Competition between local and electronic markets: How the benefit of buying online depends on where you live. Management Science, 55(1), 47–57. https://doi.org/10.1287/mnsc.1080.0932
17.
FrazierG. L.LassarW. M. (1996). Determinants of distribution intensity. Journal of Marketing, 60(4), 39–51. https://doi.org/10.1177/002224299606000405
18.
FrokjaerS.OtzenD. E. (2005). Protein drug stability: A formulation challenge. Nature Reviews Drug Discovery, 4(4), 298–306. https://doi.org/10.1038/nrd1695
19.
GAO (Government Accountability Office). (2013). Information on highest expenditure Part‐B drugs (GAO‐13‐739T). https://www.gao.gov/products/gao‐13‐739t
20.
GawandeK.BoharaA. K. (2005). Agency problems in law enforcement: Theory and application to the US Coast Guard. Management Science, 51(11), 1593–609. https://doi.org/10.1287/mnsc.1050.0422
21.
GhoseA.HanS. P. (2011). An empirical analysis of user content generation and usage behavior on the mobile Internet. Management Science, 57(9), 1671–91. https://doi.org/10.1287/mnsc.1110.1350
22.
GrayW. B.DeilyM. E. (1996). Compliance and enforcement: Air pollution regulation in the US steel industry. Journal of Environmental Economics and Management, 31(1), 96–111. https://doi.org/10.1006/jeem.1996.0034
23.
GreeneW. H. (2008). Econometric analysis. Prentice Hall.
24.
HarringtonL. (2016). A new Rx for pharma cold chains. http://www.inboundlogistics.com/cms/article/a‐new‐rx‐for‐pharma‐cold‐chains/
25.
HDA (Healthcare Distribution Association). (2022). Specialty pharmaceutical distribution: Facts, figures and trends. https://www.hda.org/publications/2022‐specialty‐pharmaceutical‐distribution‐facts‐figures‐and‐trends/
26.
HoW.ZhengT.YildizH.TalluriS. (2015). Supply chain risk management: a literature review. International Journal of Production Research, 53(16), 5031–5069.
27.
HuQ. J.SchwarzL. B. (2011). Controversial role of GPOs in healthcare‐product supply chains. Production and Operations Management, 20(1), 1–15. https://doi.org/10.1111/j.1937‐5956.2010.01121.x
28.
IMS Health. (2019). Healthcare spending among privately insured individuals under age 65. https://www.iqvia.com/insights/the‐iqvia‐institute/reports/medicine‐use‐and‐spending‐in‐the‐us‐a‐review‐of‐2018‐and‐outlook‐to‐2023
29.
KraftT.ZhengY.ErhunF. (2013). The NGO's dilemma: How to influence firms to replace a potentially hazardous substance. Manufacturing & Service Operations Management, 15(4), 649–669.
30.
LangerN.FormanC.KekreS.SunB. (2012). Ushering buyers into electronic channels: An empirical analysis. Information Systems Research, 23(4), 1212–1231. https://doi.org/10.1287/isre.1110.0410
31.
LeeE.StaelinS.YooW. S.DuR. (2013). A meta‐analysis of multibrand, multioutlet channel systems. Management Science, 59(9), 1950–1969. https://doi.org/10.1287/mnsc.1120.1692
32.
LeeH. L.WhangS. (2005). Higher supply chain security with lower cost: Lessons from total quality management. International Journal of Production Economics, 96(3), 289–300. https://doi.org/10.1016/j.ijpe.2003.06.003
33.
McCainJ. (2012). Part 1: Distribution models for biologics and other specialty pharmaceutical products. Biotechnology Healthcare, 9(2), 8–13.
34.
MercierS.VilleneuveS.MondorM.UysalI. (2017). Time–temperature management along the food cold chain: A review of recent developments. Comprehensive Reviews in Food Science and Food Safety, 16(4), 647–67. https://doi.org/10.1111/1541‐4337.12269
35.
MHA Business Summit. (2016). Specialty pharmacy trends and challenges. https://www.mhainc.com/uploadedFiles/Content/Resources/FE164_LetterSize_SPC_reprint_SPTrends.pdf
36.
MithasS.JonesJ. L. (2007). Do auction parameters affect buyer surplus in e‐auctions for procurement?Production and Operations Management, 16(4), 455–470. https://doi.org/10.1111/j.1937‐5956.2007.tb00272.x
37.
MoellerD. (2013). Specialty pharmaceuticals: Transparency, collaboration for improving drug and diagnosis coding on medical claims. Formulary, 48(11), 347–349.
38.
MorelB. H.MurphyR. (2009). Dealing with REMS challenges in drug commercialization. Pharmaceutical Commerce, 1(4), 9–11.
39.
OaxacaR. L.GeislerI. (2003). Fixed effects models with time invariant variables: A theoretical note. Economics Letters, 80(3), 373–7. https://doi.org/10.1016/S0165‐1765(03)00121‐6
40.
OverbyE.JapS. (2009). Electronic and physical market channels: A multiyear investigation in a market for products of uncertain quality. Management Science, 55(6), 940–57. https://doi.org/10.1287/mnsc.1090.0998
41.
Pharma Executive. (2013). The 2013 Pharm Exec Top 50. https://www.pharmexec.com/view/2013‐pharm‐exec‐top‐50
42.
PhRMA (Pharmaceutical Research and Manufacturers of America). (2013). The biopharmaceutical pipeline: Evolving science, hope for patients. http://phrma‐docs.phrma.org/sites/default/files/pdf/phrmapipelinereportfinal11713.pdf
43.
SantiagoM.SykutaM. (2016). Regulation and contract choice in the distribution of wine. Journal of Wine Economics, 11(2), 216–32. https://doi.org/10.1017/jwe.2015.34
44.
SarathyR. (2006). Security and the global supply chain. Transportation Journal, 45(4), 28–51. https://doi.org/10.2307/20713653
45.
SchwarzL. B.ZhaoH. (2011). The unexpected impact of information sharing on US pharmaceutical supply chains. Interfaces, 41(4), 354–364. https://doi.org/10.1287/inte.1110.0571
46.
SharmaA.MehrotraA. (2007). Choosing an optimal channel mix in multichannel environments. Industrial Marketing Management, 36(1), 21–28. https://doi.org/10.1016/j.indmarman.2006.06.012
47.
ShelleyS. (2009). Industry tackles the new REMS hurdle. https://www.pharmaceuticalcommerce.com/view/industry‐tackles‐the‐new‐rems‐hurdle
48.
SpeierC.WhippleJ. M.ClossD. J.VossM. D. (2011). Global supply chain design considerations: Mitigating product safety and security risks. Journal of Operations Management, 29(7‐8), 721–736. https://doi.org/10.1016/j.jom.2011.06.003
49.
StaigerD.StockJ. H. (1997). Instrumental variables regression with weak instruments. Econometrica, 65(3), 557–586. https://doi.org/10.2307/2171753
50.
StatonT. (2014). Genentech tightens distribution on top cancer meds, triggering blowback from hospitals. https://www.fiercepharma.com/m‐a/genentech‐tightens‐distribution‐on‐top‐cancer‐meds‐triggering‐blowback‐from‐hospitals
51.
VinhasA. S.JohnsonJ. (2019). Design and management of multi‐channel distribution in B2B environments. In C. A. Ingene, J. R. Brown, & R. P. Dant (Eds.), Handbook of research on distribution channels (pp. 443–469). Edward Elgar.
52.
WaxmanH.CorrB.MartinK.DuongS. (2018). Anticompetitive efforts to block affordable drugs: A patient's story and policy solutions. https://www.commonwealthfund.org/publications/issue‐briefs/2018/jun/anticompetitive‐efforts‐block‐affordable‐drugs‐patients‐story
53.
XuL.LiH.ZhaoH. (2022). Outcome‐based reimbursement: The solution to high drug spending?Manufacturing & Service Operations Management, 24(4), 2029–2047.
54.
XueM.HittL. M.HarkerP. T. (2007). Customer efficiency, channel usage, and firm performance in retail banking. Manufacturing & Service Operations Management, 9(4), 535–558.
55.
ZhaoH.XiongC.GavirneniS.FeinA. (2012). Fee‐For‐Service contracts in pharmaceutical distribution supply chains: Design, analysis, and management. Manufacturing & Service Operations Management, 14(4), 685–699.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
